GW3965 HCl

For research use only. Not for use in humans.

目录号:S2630

GW3965 HCl Chemical Structure

CAS No. 405911-17-3

GW3965 HCl是一种有效的,选择性LXR激动剂,作用于hLXRα和hLXRβ,无细胞试验中EC50分别为190和30 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1966.57 现货
RMB 790.51 现货
RMB 4654.57 现货
RMB 9746.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的GW3965 HCl发表文献32篇:

产品安全说明书

Liver X Receptor抑制剂选择性比较

生物活性

产品描述 GW3965 HCl是一种有效的,选择性LXR激动剂,作用于hLXRα和hLXRβ,无细胞试验中EC50分别为190和30 nM。
靶点
hLXRβ [1]
(Cell-free assay)
LXRα/SRC1 LiSA [1]
(Cell-free assay)
hLXRα [1]
(Cell-free assay)
30 nM(EC50) 125 nM(EC50) 190 nM(EC50)
体外研究

GW3965使类固醇受体共激活因子1聚集到LXRα,在无细胞配体检测试验中,EC50 为125 nM。[1] GW3965对hLXRα 和 hLXRβ表现出有效的拮抗活性,在细胞试验中EC50分别为190 nM 和30 nM。此外,GW3965也对其他核受体表现出优良的选择性。[1]在人胰岛中,GW3965 (1 μM)降低选定促炎性细胞因子,包括IL-8,单核细胞趋化蛋白-1和组织因子的表达。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MVuxNEB2VQ>? M1f1UFIxKGi{cx?= M4rBe2FkfGm4YYTpc44hd2ZiaIXtZY4hVFiUYXzwbIEh\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bkdy2neIDy[ZN{cW6pIHj1cYFvKFK[UnHsdIhiKGG2IEGwJJVOKGGodHXyJFIxKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? M4fLfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEC2PVA6Lz5{OECwOlkxQTxxYU6=
HEK293 MV[xNEB2VQ>? MkSyNlAhcHK| MYLBZ5RqfmG2aX;uJI9nKHKjdDDMXHJj\XSjIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiY3:t[ZhxemW|c3nu[{BpfW2jbjDSXHJidHCqYTDheEAyOCC3TTDh[pRmeiB{MDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyME[5NFkoRjJ6MEC2PVA6RC:jPh?=
THP1 NFztNnVHfW6ldHnvckBie3OjeR?= NGPGeo5KdmS3Y4Tpc44hd2ZiY3jvcIV{fGW{b3yg[YZndHW6IHnuJHRJWDFiY3XscJMtKEWFNUCgQUAxNjBzIN88UU4> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV6N{W3N{c,OTd3OEe1O|M9N2F-
THP1 Mn;WSpVv[3Srb36gZZN{[Xl? NIjqe5QyQCCqcoO= MUjJcoR2[3Srb36gc4Yh[2ixbHXzeIVzd2xiZX\mcJV5KGmwIGTIVFEh[2WubIOgZYZ1\XJiMUigbJJ{NCCHQ{WwJF0hOC5yMTFOwG0v NGLESmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxOlUzOSd-MUe0NVY2OjF:L3G+
COS7 MVPGeY5kfGmxbjDhd5NigQ>? NU\qbpFqOTZiaILz M1fj[mFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gUHhT[mW2YTDy[YNmeHSxcjD0doFve2[nY4Tl[EBqdiCFT2O3JINmdGy|IHHmeIVzKDF4IHjyd{BjgSC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTBiPTCwMlAyPSEQvF2u M2XXO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUi3OVc{Lz5zN{W4O|U4OzxxYU6=
COS7 Mlf5SpVv[3Srb36gZZN{[Xl? NXnMcoplSWO2aY\heIlwdiCxZjDMXHJj\XSjIHPvMZRz[W6|ZnXjeIVlKGmwIFPPV|ch[2WubIOge4l1cCCUWGLhcJBp[SCkeTDy[ZBwenSncjD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjBzNTFOwG0v M4X2S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG2OVIyLz5zN{SxOlUzOTxxYU6=
THP1 MVLBcpRqcW6obHHtcYF1d3K7IHHzd4F6 M3PHdVYhcHK| M2DZbWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZYdicW6|dDDoeY1idiCWSGCxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhUUx4IIDyc4R2[3Srb36gZYZ1\XJiNjDodpMh[nliRVzJV2EtKEmFNUCgQUAxNjB{IN88UU4> NVLzV2dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NFA4PjdpPkG4PFAxPzZ5PD;hQi=>
THP1 M3zpW2Z2dmO2aX;uJIF{e2G7 M{PBXGFod26rc4SgZYN1cX[rdImgZZQhT0GOLXzpcotm\CCqdX3hckBNYFKkZYThJIV5eHKnc4Pl[EBqdiCWSGCxJINmdGy|IHHzd4V{e2WmIHHzJJN1cW23bHH0bY9vKG:oIHPvMYFkfGm4YYTvdkBz\WO{dXn0cYVvfCCkeTDGVmVVKGG|c3H5MEBGSzVyIE2gNE4xOjdizszNMi=> MnnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4NkW4PVcoRjF5Nk[1PFk4RC:jPh?=
RAW264.7 MXfGeY5kfGmxbjDhd5NigQ>? M4PMVVI1KGi{cx?= NWqwUnlVUW6mdXP0bY9vKG:oIGuzTH1kcG:uZYP0[ZJwdCCnZn\seZghcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgcI9i\GWmIIfpeIgh[WOndInsZZRm\C2ORFygZYZ1\XJiMkSgbJJ{NCCHQ{WwJF0hOC5yMkmg{txONg>? NYXIWpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVc{ODRpPkG5O|E4OzB2PD;hQi=>
THP1 MXvGeY5kfGmxbjDhd5NigQ>? M13ifXN1cW23bHH0bY9vKG:oIGuzTH1kcG:uZYP0[ZJwdCCnZn\seZghcW5iaIXtZY4hXEiSMTDmc4FuKGOnbHzzJIxw[WSnZDD3bZRpKGGlLVzEUEwhTUN3MDC9JFAvODNzIN88UU4> NFzCR2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm3N|I5QCd-MUi5O|MzQDh:L3G+
CV1 M4f0VGZ2dmO2aX;uJIF{e2G7 NVr4Vm9xSW62YXfvcol{fCCjY4Tpeol1gSCjdDDMXHJj\XSjIHzp[4Fv\CCkaX7kbY5oKGSxbXHpckBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHQyOzF5LXnu[JVk\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbEStV3JEOSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR|UxKD1iMD6wN|k5OSEQvF2u NVPKeJRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFUyODJpPkKwN|Q2OTB{PD;hQi=>
THP1 MnvMSpVv[3Srb36gZZN{[Xl? NIC2VGpC\2:waYP0JIFkfGm4aYT5JIF1KEeDTD3sbY5s\WRiaIXtZY4hVFiUYXzwbIEh\XiycnXzd4VlKGmwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gZ49i[3SrdnH0c5IhemWlcoXpeI1mdnRiYomgSnJGXCCjc4PhfUwhTUN3MDC9JFAvODl5IN88UU4> M33uXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[1PFk4Lz5zN{[2OVg6PzxxYU6=
CV1 NHzVc2xHfW6ldHnvckBie3OjeR?= NF3wZ4xCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFzYVoFteGijIHzp[4Fv\CCkaX7kbY5oKGSxbXHpckBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHQyOzF5LXnu[JVk\WRidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGmwIHHmdolk[W5iZ4Ll[Y4hdW:wa3X5JGNXOSClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKEejbEStV3JEOSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR|UxKD1iMD6xJO69VS5? M3rhOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{S1NVAzLz5{MEO0OVExOjxxYU6=
SH-SY5Y MoXGSpVv[3Srb36gZZN{[Xl? MnXrNlQhcHK| M1ntfWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gUHhT[mW2YTDlfJBz\XO|ZXSgbY4hcHWvYX6gV2guW1l3WTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuVEKGIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTBiPTCwMlE{KM7:TT6= M2HVO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mk[0OFgyLz5zOUK2OFQ5OTxxYU6=
HepG2 M1nB[mZ2dmO2aX;uJIF{e2G7 MWfF[oZm[3Rib36gV3JGSlBzYzDn[Y5mKGW6cILld5Nqd25iaX6gbJVu[W5iSHXwS|Ih[2WubIOsJGVEPTBiPTCwMlIyKM7:TT6= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl5M{K4PEc,OTh7N{OyPFg9N2F-
HuH7 NInIU4tHfW6ldHnvckBie3OjeR?= Mkn1RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDy[YNwdWKrbnHueEBNYFKkZYThJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCrbjDoeY1idiCKdVi3JINmdGy|IHPvMZRz[W6|ZnXjeIVlKHerdHig[pV{\WRiR3HsOE1FSkRiYomgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5|MTFOwG0v NHz0bW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm3N|I5QCd-MUi5O|MzQDh:L3G+
SH-SY5Y M4XPSWZ2dmO2aX;uJIF{e2G7 NFzJTlczPCCqcoO= MVPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIFzYVoFteGijIHX4dJJme3OnZDDpckBpfW2jbjDTTE1UYTW\IHPlcIx{KGOxLYTyZY5{\mWldHXkJJdqfGhiR3HsOE1NSkRiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OCB;IECuN|Eh|ryPLh?= M1zUdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mk[0OFgyLz5zOUK2OFQ5OTxxYU6=
CHO MmDaSpVv[3Srb36gZZN{[Xl? NETWd4NC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGxZWiCkZYThJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYomgdoVxd3K2ZYKgZZN{[XluIFXDOVAhRSByLkSxJO69VS5? NXzh[npSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUewN|QyOTlpPkG3NFM1OTF7PD;hQi=>
CHOK1 NG\PUJFHfW6ldHnvckBie3OjeR?= M1:0WFI1KGi{cx?= Mn2wRYdwdmm|dDDhZ5Rqfmm2eTDheEBI[Wx2LYTh[4dm\CCOWGLi[ZRiKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFPIU2syKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUCgQUAxNjR{IN88UU4> NUfENok4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|c3PjRpPkK1Olc4PjZ2PD;hQi=>
THP1 MlnmSpVv[3Srb36gZZN{[Xl? M3TZOGVn\mWldDDvckBCSkODMTDn[Y5mKGW6cILld5Nqd25iaX6gbJVu[W5iZHnm[oVz\W62aXH0[YQhXEiSMTDj[YxteyxiRVO1NEA:KDBwNEO0JO69VS5? NEL5fIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm3N|I5QCd-MUi5O|MzQDh:L3G+
CV1 NH7HO4hHfW6ldHnvckBie3OjeR?= Mn7xRYdwdmm|dDDhZ5Rqfmm2eTDheEBNYFKkZYThJIxq\2GwZDDibY5lcW6pIHTvcYFqdi2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR3YyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuND3TVmMyKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFXDOVAhRSByLkWwNVE6KM7:TT6= MlzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|NEWxNFIoRjJyM{S1NVAzRC:jPh?=
HuH7 Mmq5SpVv[3Srb36gZZN{[Xl? NWXRU3NESWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBz\WOxbXLpcoFvfCCOWGLhcJBp[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6gbY4hcHWvYX6gTJVJPyClZXzsd{Bkdy22cnHud4Zm[3SnZDD3bZRpKG[3c3XkJGdidDRvRFLEJIJ6KHS{YX7zZYN1cX[jdHnvckBie3OjeTygSWM2OCB;IECuOlYh|ryPLh?= NH;h[pE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm3N|I5QCd-MUi5O|MzQDh:L3G+
CV1 NWXxdmx2TnWwY4Tpc44h[XO|YYm= NXThTlFtSWexbnnzeEBi[3Srdnn0fUBifCCOWGLhcJBp[SCuaXfhcoQh[mmwZHnu[{Bld22jaX6tcYVlcWG2ZXSgeJJidnOlcnnweIlwdmGuIHHjeIl3cXS7IHnuJIFnemmlYX6g[5Jm\W5ibX;ub4V6KEOYMTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuW1KFMTDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGG|c3H5MEBGSzVyIE2gNE44QTR|MzFOwG0v NEPjOJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OVExOid-MkCzOFUyODJ:L3G+
CHOK1 NUPxRY5wTnWwY4Tpc44h[XO|YYm= NV\BUJE6OjRiaILz M2HSTGFod26rc4SgZYN1cX[rdImgZZQhT2GuND30ZYdo\WRiTGjSZYxxcGFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gR2hQUzFiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDFwMzFOwG0v NWL6VnM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|c3PjRpPkK1Olc4PjZ2PD;hQi=>
HepG2 NXjmWJB3TnWwY4Tpc44h[XO|YYm= MUHF[oZm[3Rib36geJJq\2y7Y3XybYRmKGGlY4XteYxifGmxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{whTUN3MDC9JFIvODB{IN88UU4> NIHjS|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEm3N|I5QCd-MUi5O|MzQDh:L3G+
HepG2 NGrv[GJHfW6ldHnvckBie3OjeR?= M4rDSlUxOCCwTR?= MXPJcohq[mm2aX;uJI9nKDJvKEOtLFMuMCh{LXPocI9zdy1|LTj0dolndHWxcn;t[ZRpgWxrYnXufpltMSh{LEKt[IlxcGWweXzleIh6dCmjbXnuc{lxem:yb4j5LZBp\W67bDnhZ4V1cWNiYXPp[E1qdmS3Y3XkJJNz\WKyMXOgcXJPSSCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF1KDVyMDDuUS=> M3HnU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO|Y4Lz5zOEiwNFc3PzxxYU6=
HepG2 MnPPSpVv[3Srb36gZZN{[Xl? MUK1NFAhdk1? NGXWW3hKdmirYnn0bY9vKG:oIEKtLFMuMDNvKDiyMYNpdG:{bz2zMUh1emmobIXvdo9u\XSqeXypZoVvgnmuKTiyMFIu\GmyaHXufYxmfGi7bDnhcYlvdymycn;wc5h6MXCqZX75cEli[2W2aXOgZYNq\C2rbnT1Z4VlKG[jczDtVm5CKGW6cILld5Nqd25iaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZQhPTByIH7N MkLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO|Y4RC:jPh?=
RAW264.7 M{XpOmZ2dmO2aX;uJIF{e2G7 M2r2fFEhfU1? M3HacnJm\HWldHnvckBw\iCOUGOtd5RqdXWuYYTl[EBqVk:VIHflcoUh\XiycnXzd4lwdiCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{BmgHC{ZYPzbY5oKEy[UnHsdIhiKGG2IEGgeW0h[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 NIXk[nc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
RAW264.7 M2XENmZ2dmO2aX;uJIF{e2G7 NGHmWm8yKHWP MofPTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBvfWOuZXHyJINwNXKncILld5NweiC{ZXzlZZNmKG[{b32gbW5QWyCycn;tc5RmeiCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{BifCBzIIXNJIJ6KFKWLWDDVi=> M{HIUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO|Y4Lz5zOEiwNFc3PzxxYU6=
HeLa M4XnUmZ2dmO2aX;uJIF{e2G7 MXSxJJVO M2Tpdmlv\HWldHnvckBw\iCOWGLi[ZRiKFOXTV;5cIF1cW:wIHL5JHNWVU9{IHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOSC3TTDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO|Y4RC:jPh?=
HeLa M{DFXWZ2dmO2aX;uJIF{e2G7 M2jtdlEhfU1? NFG5ZndKdmS3Y4Tpc44hd2ZiTGjSZoV1[SCVVV3PfYxifGmxbjDifUBUXU2RMzDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDFidV2gZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NGfpNpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
HeLa NEX5ZopHfW6ldHnvckBie3OjeR?= NGS4S3oyKHWP M1;ESGlv\HWldHnvckBw\iCOWGLhcJBp[SCVVV3PfYxifGmxbjDifUBUXU2RMzDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDFidV2gZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M{\WbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO|Y4Lz5zOEiwNFc3PzxxYU6=
DAOY MkXxdWhVWyCjc4PhfS=> MkDSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NF;tVpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 M2LHeJFJXFNiYYPzZZk> M1fz[5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz M3Tne|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MXfxTHRUKGG|c3H5 NGHmW2JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MmPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC MXHxTHRUKGG|c3H5 MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NHe5RWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NXe5eWtjeUiWUzDhd5NigQ>? MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 MWDxTHRUKGG|c3H5 M4PJdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz NG\QOVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MlnwdWhVWyCjc4PhfS=> MmL6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= M2rnV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 MWrxTHRUKGG|c3H5 MmX2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| NGP4blg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MXLxTHRUKGG|c3H5 NUS3RY13eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MmDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD MULxTHRUKGG|c3H5 NGfuRpFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NXnhTIhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) MUjxTHRUKGG|c3H5 MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? M1G3dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30 NVLSSoxueUiWUzDhd5NigQ>? NEXwRWFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NW[3UINueUiWUzDhd5NigQ>? NXTBRlRyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NXjPOWFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Skp2 / pEGFR / EGFR / pERK / ERK ; 

PubMed: 25184494     


GW3965 treatment downregulates SKP2 and EGFR protein levels in BxPC-3 and MIA-PaCa-2 cells. Downregulation of EGFR was concomitant with a downregulation of its own phosphorylation in BxPC-3 and MIA-PaCa-2 at 5 uM GW 3965. ERK1/2 and its phosphorylation were not statistically different in any of the cell lines.

LXRα / LXRβ / ABCA1 / ABCG1; 

PubMed: 11604492     


Differentiated THP-1 macrophages were incubated for 48 h in RPMI medium plus 10% LPDS, Oxysterols [20(S)HC, 22(R)HC, or 22(S)HC, 2.0 μg/ml], synthetic LXR ligand (GW3965 or T1317, 0.1 to 10.0 μM), or RXR ligand (LG268, 50 nM).

25184494 11604492
Immunofluorescence
LAMP-1 / LDLR; 

PubMed: 23382078     


HeLa cells were cultured in 10% LPDS medium for 8 h and then treated with GW3965 (1 μM) for the indicated times. Cells were immunostained with LDLR and LAMP-1 antibodies. Nuclei were counterstained with DAPI (blue). Representative confocal images are shown. T, time; O/N, overnight.

pRelA ; 

PubMed: 26635040     


Freshly isolated PDC (plasmacytoid dendritic cells) were treated for 24 h with 1 mM of GW3965 (GW), followed by TLR7 ligand, R848 (1 mg/mL) for 45 min. Phosphorylation of the NF-κB p65 (pRelA) subunit and its cellular localization were evaluated by confocal microscopy analysis. Results from a representative experiment out of 3 using PDC from 3 different donors.

23382078 26635040
Growth inhibition assay
Cell viability; 

PubMed: 25184494     


A, B, C, PDAC cells (BxPC-3, Mia-PaCa-2, and PANC-1 cell lines, respectively) show dose-dependent decreases in cell proliferation upon treatment with increasing GW3965 concentrations. EC50 calculations indicate that BxPC-3 and Mia-PaCa-2 cells are more sensitive to ligand treatment than PANC-1 cells. 

25184494
体内研究 在小鼠体内,GW3965在10 mg/kg剂量下使ABCA1表达上调8倍,并使循环水平提高30%,Cmax为12.7 μg/mL ,t1/2为2小时。[1] 在LDLR−/−和apoE−/−小鼠体内,GW3965 (10mg/kg)诱导ABCA1 和ABCG1表达,并表现出有效的抗动脉粥样硬化活性。[2]在雄性sprague-dawley大鼠体内,GW3965降低Ang II介导的血压增加,并减少血管Ang II受体基因表达。[3]在恶性胶质瘤小鼠模型中,GW3965导致LDLR降解,增加ABCA1胆固醇外排转运体的表达,从而有效促进肿瘤细胞死亡。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
- 合并
  • Animal Models: C57BL/6 小鼠
  • Dosages: ≤10 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 16 mg/mL warmed (25.86 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 618.51
化学式

C33H31ClF3NO3.HCl

CAS号 405911-17-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to formulate the compound for mouse in vivo experiment?

  • 回答:

    S2630 GW3965 HCl can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/mL as a homogeneous suspension. This vehicle is suitable for oral gavage to mice.

免费分装抑制剂

相关Liver X Receptor产品

Tags: 购买GW3965 HCl | GW3965 HCl供应商 | 采购GW3965 HCl | GW3965 HCl价格 | GW3965 HCl生产 | 订购GW3965 HCl | GW3965 HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID